This study is testing a new gene therapy called AAVAnc80-antiVEGF, delivered using the Akouos Delivery Device, for people with vestibular schwannoma. Vestibular schwannoma is a non-cancerous tumor that grows on the nerve connecting the ear to the brain. The therapy aims to target VEGF, a protein involved in blood vessel growth, which may contribute to tumor growth. We are looking for people aged 18 and older who have a progressive vestibular schwannoma larger than 2 mm in one ear and profound hearing loss in that same ear. The main goal is to see how safe the AAVAnc80-antiVEGF therapy is and if the delivery device works as intended. The study is currently recruiting 27 participants.

Study design

This is an interventional study with a planned enrollment of 27 participants. It will evaluate three different dose levels of the AAVAnc80-antiVEGF therapy.

What's involved

You would receive a single dose of AAVAnc80-antiVEGF delivered to one ear using the Akouos Delivery Device. You would also need to comply with all trial requirements, including participating in a separate long-term follow-up study.

Compensation

Not stated in the trial record.

Follow-up

The study will measure adverse events through trial completion, which is approximately one year. You will also participate in a separate long-term follow-up study after the trial ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.